Notice2021-16295
Foreign-Trade Zone (FTZ) 22-Chicago, Illinois; Notification of Proposed Production Activity; AbbVie, Inc. (Pharmaceutical Products); North Chicago and Lake County, Illinois
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
July 30, 2021
Issuing agencies
Commerce DepartmentForeign-Trade Zones Board
Full Text
<html>
<head>
<title>Federal Register, Volume 86 Issue 144 (Friday, July 30, 2021)</title>
</head>
<body><pre>
[Federal Register Volume 86, Number 144 (Friday, July 30, 2021)]
[Notices]
[Page 41008]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2021-16295]
-----------------------------------------------------------------------
DEPARTMENT OF COMMERCE
Foreign-Trade Zones Board
[B-55-2021]
Foreign-Trade Zone (FTZ) 22--Chicago, Illinois; Notification of
Proposed Production Activity; AbbVie, Inc. (Pharmaceutical Products);
North Chicago and Lake County, Illinois
AbbVie, Inc. (AbbVie), submitted a notification of proposed
production activity to the FTZ Board for its facilities in North
Chicago and Lake County, Illinois. The notification conforming to the
requirements of the regulations of the FTZ Board (15 CFR 400.22) was
received on July 16, 2021.
AbbVie already has authority to produce pharmaceutical products
within Subzone 22S. The current request would add a finished product
and foreign status materials to the scope of authority. Pursuant to 15
CFR 400.14(b), additional FTZ authority would be limited to the
specific foreign-status materials and specific finished product
described in the submitted notification (as described below) and
subsequently authorized by the FTZ Board.
Production under FTZ procedures could exempt AbbVie from customs
duty payments on the foreign-status materials/components used in export
production. On its domestic sales, for the foreign-status materials/
components noted below and in the existing scope of authority, AbbVie
would be able to choose the duty rates during customs entry procedures
that apply to upadacitinib intermediate material (duty rate 6.5%).
AbbVie would be able to avoid duty on foreign-status components which
become scrap/waste. Customs duties also could possibly be deferred or
reduced on foreign-status production equipment.
The materials sourced from abroad are 2-Amino-3,5-dibromopyrazine
and potassium tert-butylate (duty rate ranges from 3.7 to 6.5%). The
request indicates that the foreign-status materials are subject to
duties under Section 301 of the Trade Act of 1974 (Section 301),
depending on the country of origin. The applicable Section 301
decisions require subject merchandise to be admitted to FTZs in
privileged foreign status (19 CFR 146.41).
Public comment is invited from interested parties. Submissions
shall be addressed to the Board's Executive Secretary and sent to:
<a href="/cdn-cgi/l/email-protection#2442505e6450564540410a434b52"><span class="__cf_email__" data-cfemail="1d7b69675d696f7c7978337a726b">[email protected]</span></a>. The closing period for their receipt is September 8,
2021.
A copy of the notification will be available for public inspection
in the ``Reading Room'' section of the Board's website, which is
accessible via <a href="http://www.trade.gov/ftz">www.trade.gov/ftz</a>.
For further information, contact Christopher Wedderburn at
<a href="/cdn-cgi/l/email-protection#37745f455e44196052535352455542455977434556535219505841"><span class="__cf_email__" data-cfemail="5d1e352f342e730a383939382f3f282f331d292f3c3938733a322b">[email protected]</span></a>.
Dated: July 27, 2021.
Andrew McGilvray,
Executive Secretary.
[FR Doc. 2021-16295 Filed 7-29-21; 8:45 am]
BILLING CODE 3510-DS-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on July 30, 2021.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.